<Table 1: S100A8/S100A9 functions and association with inflammatory conditions.
Function |
Ref |
Murine: - Neutrophil and monocyte chemotaxis (S100A8) |
|
- Activate TLR4 and amplify inflammatory responses (S100A8) |
[9] |
- Inhibit macrophage spreading and phagocytosis of adherent |
|
peritoneal cells (S100A9) |
[57] |
- Oxidant scavenger (S100A8) |
[56] |
- Reduce H2O2 release from activated macrophage (S100A9) |
[58] |
Human: - Neutrophil chemotaxis (S100A8/S100A9) |
|
- Upregulate Mac-1 expression (S100A8? S100A9) |
|
- Promote intercellular arachidonic acid transport (S100A8/S100A9) |
[18] |
- Antimicrobial defense (S100A8/S100A9) |
[59] |
- Inhibit fibrin formation (S100A9) |
[60] |
- Sequester intracellular Zn2+ (S100A8/S100A9) |
[61] |
- Oxidant scavenger and NO shuttle (S100A8) |
|
- Reduce H2O2 release from activated macrophage (S100A9) |
[58] |
- Proinflammatory; enhance expression of proinflammatory cytokines |
|
and adhesion molecules (S100A8/S100A9) |
|
- Anti-inflammatory; recombinant proteins reduced LPS-induced systemic |
|
release of IL-6 and NO in rats (S100A8/S100A9) |
[65] |
Association with inflammatory disease/disorder |
|
Murine: - Arthritis (S100A8/S100A9) |
[66] |
- Abdominal sepsis |
|
- Pneumonia-derived sepsis |
[68] |
- LPS-induced endotoxemia |
|
- Autoimmune myocarditis |
[70] |
Human: - Arthritis (S100A8/S100A9) |
|
- Inflammatory bowel disease (S100A8/S100A9) |
[74] |
- Systemic inflammation (S100A8/S100A9) |
|
- Pancreatitis (S100A8/S100A9) |
[77] |
- Sepsis (S100A8/S100A9) |
|
- Lupus erythematosus |
[80] |